Expert Interviews

Assessing the Burden of Type 1 Diabetes
December 19, 2024

Panelists discuss how Type 1 diabetes imposes significant physical, emotional, and financial burdens on patients through the lifelong need for insulin therapy, blood glucose monitoring, lifestyle modifications, and management of potential complications.

Vaccination Information and Educational Resources from the National Foundation for Infectious Diseases
December 19, 2024

Robert Hopkins, Jr, MD, NFID medical director, details a range of resources on the foundation's website including in-depth vaccine recommendations, live webinars, plus much more.

A Vaccination Imperative: "Please, Let's Do It," NFID Medical Director Robert Hopkins, Jr, MD, Urges
December 18, 2024

The National Foundation for Infectious Diseases medical director appeals to the community at large to set politics and personal grievance aside and to "first, do no harm."

The Importance of the Patient-Provider Relationship
December 17, 2024

Experts talk about the impact of a collaborative and supportive patient-provider relationship in the management of IBS-C and CIC.

Premature Treatment Discontinuation (Time to Response)
December 17, 2024

Thought leaders explore premature treatment discontinuation and some of the reasons leading to it, such as time to response and safety in regards to the use of prescription therapies for IBS-C and CIC.

Over-the-Counter and Prescription Treatment Guidelines and Use
December 17, 2024

Experts discuss the current use of OTC and review guidelines for prescription treatments for IBS-C and CIC.

IBS-C and CIC Overview
December 17, 2024

Thought leaders review prevalence, common symptoms, and patient burden of IBS-C and CIC.

Future of Obesity Care: 3 Wishes from Thought Leader Donna Ryan, MD
December 17, 2024

When asked about her 3 wishes for the future of obesity care, Donna Ryan, MD, told Patient Care that she had just one: access.

Expert Perspectives 2024: Breakthrough Therapy for Congenital Adrenal Hyperplasia with PI Richard Auchus, MD, PhD
December 17, 2024

The lead investigator of the largest clinical trial program in people with CAH discusses the condition, its burden, and the novel drug just approved that will change lives.

Richard J Auchus, MD, PhD, Details Pivotal Phase 3 Trial That Supported FDA Approval of Crinecerfont for Congenital Adrenal Hyperplasia
December 16, 2024

Auchus details findings from the unique study of the CRF-1 antagonist crinecerfont, the first new therapy for CAH approved in 70 years.